<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086575</url>
  </required_header>
  <id_info>
    <org_study_id>OrPHEe study</org_study_id>
    <secondary_id>2021-A00468-33</secondary_id>
    <nct_id>NCT05086575</nct_id>
  </id_info>
  <brief_title>Observatory of Patients With Haemophilia B Treated by IdElvion®</brief_title>
  <acronym>OrPHEe</acronym>
  <official_title>Observatory of Patients With Haemophilia B Treated by IdElvion®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OrPHEe is a non-interventional, prospective and national study which aim is to record real&#xD;
      life data in haemophilia B French patients treated with Idelvion® to confirm the efficacy and&#xD;
      safety of this product established in clinical development studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemophilia B is a congenital coagulation disorder caused by a deficiency or anomaly of&#xD;
      coagulation factor IX (FIX).&#xD;
&#xD;
      The severity of the haemophilia depends on the extent of the FIX deficiency with clinical&#xD;
      manifestations differing depending on the location of the bleed.&#xD;
&#xD;
      Treatment of this disease involves the administration of the deficient factor, i.e. FIX, to&#xD;
      patients. Depending on the severity of the disease and context, a range of treatment regimens&#xD;
      are available (long-term prophylactic treatment for the prevention of non-surgical bleeds,&#xD;
      short-term prophylactic treatment for high-risk periods, treatment for the prevention of&#xD;
      surgical bleeds or on-demand curative treatment).&#xD;
&#xD;
      CSL Behring has developed a long-acting recombinant FIX, i.e. rIX-FP (Idelvion®), to extend&#xD;
      the intervals between the administrations of treatment while also providing a therapeutic&#xD;
      benefit. Data from clinical studies clearly confirm the therapeutic benefit of Idelvion® in&#xD;
      adult and paediatric patients with haemophilia B previously receiving an on-demand treatment&#xD;
      for bleeding episodes, for long-term prophylaxis, as well as in patients undergoing surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annual bleeding rates (overall, spontaneous and traumatic) under the scope of long-term prophylaxis or on-demand treatment of non-surgical bleeding events</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of spontaneous bleeding events per patient</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Idelvion® infusions and doses injected by infusion required to prevent and resolve non-surgical bleeding episodes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of non-surgical bleeding episodes</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of infusions and total dose of Idelvion® (in IU/kg) required to prevent or treat surgical bleeding episodes</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of surgical bleeding episodes</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of infusions and total dose of Idelvion® (in IU/kg) required to cover a high risk of bleeding</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of infusions and total dose of Factor IX consumed in the year prior to taking Idelvion®</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of infusions and total dose of Idelvion®</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type and incidence of adverse events (AE) in particular severe AE,and AE related to Idelvion®</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of the following questionnaire: EQ-5D-3L for adults</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of the following questionnaire: EQ-5D-Y for children from 8 to 12 years</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Haemophilia B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Haemophilia B patients treated with Idelvion®&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have agreed to participate in the observatory after receiving written information on&#xD;
             the purpose of the study and the personal data to be collected (agreement of parents&#xD;
             for under-age patients);&#xD;
&#xD;
          -  Present with haemophilia B and are currently being treated or have previously been&#xD;
             treated with Idelvion® as a long-term prophylactic treatment, on-demand treatment or&#xD;
             short-term treatment for surgical procedures or to cover periods with a high-risk of&#xD;
             bleeding.&#xD;
&#xD;
          -  Do not have FIX targeted antibodies at the time of the inclusion visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal by the patient or his/her legal representative to participate in the study;&#xD;
&#xD;
          -  Existence of a contraindication to the use of Idelvion® treatment (known&#xD;
             hypersensitivity to FIX or hamster proteins);&#xD;
&#xD;
          -  Simultaneous participation in an interventional clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Catovic</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Bracquart</last_name>
    <phone>610-878-4000</phone>
    <email>diane.bracquart@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRC-MHC Hôpital Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nangis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot - CH Versailles</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FIX, Coagulation FIX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

